NICE approves Taxol for ovarian cancerBMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7245.1293/a (Published 13 May 2000) Cite this as: BMJ 2000;320:1293
- Zosia Kmietowicz
The cytotoxic drug paclitaxel (Taxol) is to be made available to all women in Englandand Wales with ovarian cancer following the long awaited ruling by the National Institute for Clinical Excellence (NICE).
Paclitaxel, in combination with platinum, should be the first line treatment after surgery in all cases of ovarian cancer and should also be used to treat women whose cancer has recurred or has failed to respond to other forms of treatment, according to NICE.
The recommendation is expected to cost the NHS an additional £7m ($11.2m) a year to treat …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial